Nursing care and management of adverse events for patients with BRAF^V600E-mutant metastatic colorectal cancer receiving encorafenib in combination with cetuximab: a review.

ABSTRACT: Encorafenib is a B-Raf proto-oncogene serine/threonine-protein kinase (BRAF) inhibitor, approved in the EU and USA, in combination with the epidermal growth factor receptor (EGFR) inhibitor cetuximab, for the treatment of patients with BRAF^V600E-mutant metastatic colorectal cancer (mCRC). In the pivotal BEACON CRC trial, patients achieved longer survival with encorafenib in combination with cetuximab vs. conventional chemotherapy. This targeted therapy regimen is also generally better tolerated than cytotoxic treatments. However, patients may present with adverse events unique to the regimen and characteristic of BRAF and EGFR inhibitors, which produce their own set of challenges. Nurses play an essential role in navigating the care of patients with BRAF^V600E-mutant m

SUBMITTER: Fowler M 

PROVIDER: S-EPMC9989561 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature